Journal of Developmental Medicine(Electronic Version)  2025, Vol. 13 Issue (4): 287-292 DOI: 10.3969/j.issn.2095-5340.2025.04.007 |
|
|
|
|
|
|
| Application of totally implantable venous access port in children with leukemia |
| Gao Peng, Lyu Qiuchen, Yang Di, et al
|
(1. Department of Surgery, Heilongjiang Hospital Affiliated to Beijing Children's Hospital, Capital Medical University, Heilongjiang, Harbin 150010, China; 2. Department of Ultrasound, Heilongjiang Hospital Affiliated to Beijing Children's Hospital, Capital Medical University, Heilongjiang, Harbin 150010, China; 3. Department of Anesthesiology, Heilongjiang
Hospital Affiliated to Beijing Children's Hospital, Capital Medical University, Heilongjiang, Harbin 150010, China; 4.Department of Hematology, Heilongjiang Hospital Affiliated to Beijing Children's Hospital, Capital Medical University, Heilongjiang, Harbin 150010, China)
|
|
|
|
Abstract 【Abstract】 Objective To explore the characteristics and technical improvements of totally implantable venous access port (TIVAP) in surgical procedures and postoperative maintenance for children with leukemia.Method Using a retrospective study method, data were collected from five children with leukemia who underwent TIVAP implantation at Heilongjiang Hospital Affiliated to Beijing Children's Hospital, Capital Medical University from September 2020 to December 2023. Information related to the use andmaintenance of TIVAP was analyzed, including surgical procedures, postoperative maintenance, occurrence and management of short-term and long-term complications, and port removal. Result All five children
successfully underwent ultrasound-guided internal jugular vein catheterization and TIVAP implantation under general anesthesia. Among them, one was male and four were female, with a median age of (1.92±1.65) years (ranged from 0.39 to 4.66 years). Catheterization was performed via the right internal jugular vein in four cases and the left internal jugular vein in one case. One child died due to disease progression (1 year after port placement), one child was currently using the port, two children underwent unplanned port removal due to catheter-related bloodstream infection (CRBSI) during "routine hospital maintenance therapy" (13 months and 19 months after port implantation, respectively), and one child had the port removed as planned after completing chemotherapy. During use, complications included drug extravasation in two cases, CRBSI in two cases, and catheter thrombosis in one case. Ultrasound before port removal indicated varying degrees of fibrin
sheath formation around the catheter in three cases. Conclusion TIVAP can meet the intravenous infusion needs of children undergoing chemotherapy. When used in accordance with standardized procedures, TIVAP are safe, offer significant advantages, and are highly practical.
|
|
Received: 14 June 2024
Published: 31 July 2025
|
|
|
|
|
|
